FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048312758> ?p ?o ?g. }

• W3048312758 endingPage "939" @default.
• W3048312758 startingPage "930" @default.
• W3048312758 abstract "<h2>Abstract</h2><h3>Objective</h3> Current guidelines recommend single-agent antiplatelet therapy for patients with symptomatic peripheral artery disease and consideration of dual antiplatelet therapy (DAPT) after surgical revascularization. The objective of this study was both to explore prescribing patterns of single antiplatelet therapy vs DAPT after lower extremity bypass surgery and to investigate the effects of antiplatelet therapy on bypass graft patency. <h3>Methods</h3> A retrospective analysis of prospectively collected nonemergent infrainguinal lower extremity bypass operations entered in the national Vascular Quality Initiative (2003-2018) with captured long-term follow-up was performed. Patients discharged on aspirin monotherapy or DAPT were identified. Linear regression investigated temporal trends in antiplatelet use. Multivariable Cox regression investigated predictors of primary, primary assisted, and secondary patency. <h3>Results</h3> Of the 13,020 patients investigated, 52.2% were discharged on aspirin monotherapy and 47.8% on DAPT. The proportion of patients discharged on DAPT increased from 10.6% in 2003 to 60.6% in 2018 (<i>P</i> < .001). The DAPT cohort was younger, had higher rates of medical (hypertension, diabetes, congestive heart failure, chronic obstructive pulmonary disease) and atherosclerotic (coronary artery disease, prior coronary artery bypass graft or percutaneous coronary intervention, prior lower extremity intervention) comorbidities, and had higher risk bypass procedures (more distal targets, prior inflow bypass procedure, prosthetic conduit use). Multivariable Cox regression analysis did not show any difference between the DAPT and aspirin cohorts in primary patency (hazard ratio [HR], 0.98; 95% confidence interval [CI], 0.88-1.10; <i>P</i> = .78), primary assisted patency (HR, 0.93; 95% CI, 0.80-1.07; <i>P</i> = .30), or secondary patency (HR, 0.88; 95% CI, 0.74-1.06; <i>P</i> = .18). On subgroup analysis based on bypass conduit, DAPT was found to have a protective effect on patency only in the prosthetic bypass cohort (primary patency: HR, 0.81 [95% CI, 0.66-1.00; <i>P</i> = .05]; primary assisted patency: HR, 0.74 [95% CI, 0.58-0.94; <i>P</i> = .01]; and secondary patency: HR, 0.60 [95% CI, 0.44-0.82; <i>P</i> < .001]). No patency differences were observed on adjusted subgroup analysis for the other bypass conduits. <h3>Conclusions</h3> A significant and increasing proportion of patients are discharged on DAPT after lower extremity bypass revascularization. These patients represent a higher risk cohort with more medical comorbidities and higher risk bypass features. After controlling for these differences, DAPT therapy had no beneficial effect on overall bypass graft patency or major adverse limb events. However, on subgroup analysis, DAPT was associated with improved bypass graft patency in patients receiving prosthetic bypass conduits. Further study is warranted to investigate optimal duration of DAPT therapy and its possible bleeding complications in prosthetic bypass patients." @default.
• W3048312758 created "2020-08-13" @default.
• W3048312758 creator A5018177681 @default.
• W3048312758 creator A5018903421 @default.
• W3048312758 creator A5021014320 @default.
• W3048312758 creator A5025599829 @default.
• W3048312758 creator A5055215636 @default.
• W3048312758 creator A5071130305 @default.
• W3048312758 creator A5082890040 @default.
• W3048312758 creator A5088367060 @default.
• W3048312758 date "2021-03-01" @default.
• W3048312758 modified "2023-09-30" @default.
• W3048312758 title "Effects of dual antiplatelet therapy on graft patency after lower extremity bypass" @default.
• W3048312758 cites W13897408 @default.
• W3048312758 cites W1975757685 @default.
• W3048312758 cites W2007069182 @default.
• W3048312758 cites W2024352468 @default.
• W3048312758 cites W2037500444 @default.
• W3048312758 cites W2071392303 @default.
• W3048312758 cites W2078178450 @default.
• W3048312758 cites W2079595856 @default.
• W3048312758 cites W2082336558 @default.
• W3048312758 cites W2100209149 @default.
• W3048312758 cites W2140136269 @default.
• W3048312758 cites W2153281494 @default.
• W3048312758 cites W2315630371 @default.
• W3048312758 cites W2430015321 @default.
• W3048312758 cites W2510098524 @default.
• W3048312758 cites W2556838984 @default.
• W3048312758 cites W2574319255 @default.
• W3048312758 cites W2615256918 @default.
• W3048312758 cites W2804382481 @default.
• W3048312758 cites W2811185415 @default.
• W3048312758 cites W2975859535 @default.
• W3048312758 doi "https://doi.org/10.1016/j.jvs.2020.06.127" @default.
• W3048312758 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32777321" @default.
• W3048312758 hasPublicationYear "2021" @default.
• W3048312758 type Work @default.
• W3048312758 sameAs 3048312758 @default.
• W3048312758 citedByCount "9" @default.
• W3048312758 countsByYear W30483127582021 @default.
• W3048312758 countsByYear W30483127582022 @default.
• W3048312758 countsByYear W30483127582023 @default.
• W3048312758 crossrefType "journal-article" @default.
• W3048312758 hasAuthorship W3048312758A5018177681 @default.
• W3048312758 hasAuthorship W3048312758A5018903421 @default.
• W3048312758 hasAuthorship W3048312758A5021014320 @default.
• W3048312758 hasAuthorship W3048312758A5025599829 @default.
• W3048312758 hasAuthorship W3048312758A5055215636 @default.
• W3048312758 hasAuthorship W3048312758A5071130305 @default.
• W3048312758 hasAuthorship W3048312758A5082890040 @default.
• W3048312758 hasAuthorship W3048312758A5088367060 @default.
• W3048312758 hasBestOaLocation W30483127581 @default.
• W3048312758 hasConcept C124952713 @default.
• W3048312758 hasConcept C141071460 @default.
• W3048312758 hasConcept C142362112 @default.
• W3048312758 hasConcept C164705383 @default.
• W3048312758 hasConcept C2780980858 @default.
• W3048312758 hasConcept C71924100 @default.
• W3048312758 hasConceptScore W3048312758C124952713 @default.
• W3048312758 hasConceptScore W3048312758C141071460 @default.
• W3048312758 hasConceptScore W3048312758C142362112 @default.
• W3048312758 hasConceptScore W3048312758C164705383 @default.
• W3048312758 hasConceptScore W3048312758C2780980858 @default.
• W3048312758 hasConceptScore W3048312758C71924100 @default.
• W3048312758 hasIssue "3" @default.
• W3048312758 hasLocation W30483127581 @default.
• W3048312758 hasOpenAccess W3048312758 @default.
• W3048312758 hasPrimaryLocation W30483127581 @default.
• W3048312758 hasRelatedWork W2002120878 @default.
• W3048312758 hasRelatedWork W2003938723 @default.
• W3048312758 hasRelatedWork W2047967234 @default.
• W3048312758 hasRelatedWork W2118496982 @default.
• W3048312758 hasRelatedWork W2364998975 @default.
• W3048312758 hasRelatedWork W2369162477 @default.
• W3048312758 hasRelatedWork W2439875401 @default.
• W3048312758 hasRelatedWork W4238867864 @default.
• W3048312758 hasRelatedWork W2519357708 @default.
• W3048312758 hasRelatedWork W2525756941 @default.
• W3048312758 hasVolume "73" @default.
• W3048312758 isParatext "false" @default.
• W3048312758 isRetracted "false" @default.
• W3048312758 magId "3048312758" @default.
• W3048312758 workType "article" @default.